Haemonetics (HAE) Set to Announce Earnings on Thursday

Haemonetics (NYSE:HAE) is scheduled to be posting its quarterly earnings results before the market opens on Thursday, May 9th. Analysts expect Haemonetics to post earnings of $0.88 per share for the quarter. Haemonetics has set its FY 2024 guidance at 3.900-4.000 EPS and its FY24 guidance at $3.90-4.00 EPS.Individual that are interested in participating in the company’s earnings conference call can do so using this link.

Haemonetics (NYSE:HAE) last issued its quarterly earnings results on Thursday, February 8th. The medical instruments supplier reported $1.04 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.94 by $0.10. The firm had revenue of $336.20 million during the quarter, compared to analyst estimates of $320.84 million. Haemonetics had a return on equity of 22.37% and a net margin of 9.97%. The firm’s quarterly revenue was up 10.1% on a year-over-year basis. During the same period last year, the company posted $0.85 EPS. On average, analysts expect Haemonetics to post $4 EPS for the current fiscal year and $4 EPS for the next fiscal year.

Haemonetics Stock Performance

Shares of NYSE HAE opened at $92.26 on Thursday. The stock has a fifty day moving average price of $81.58 and a two-hundred day moving average price of $82.67. The company has a debt-to-equity ratio of 0.91, a quick ratio of 1.76 and a current ratio of 2.92. The firm has a market cap of $4.69 billion, a P/E ratio of 37.50, a PEG ratio of 2.16 and a beta of 0.36. Haemonetics has a 1 year low of $70.74 and a 1 year high of $95.26.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on the company. TheStreet lowered Haemonetics from a “b-” rating to a “c+” rating in a research note on Thursday, February 29th. Barrington Research reissued an “outperform” rating and set a $105.00 price objective on shares of Haemonetics in a research note on Friday, April 12th. Finally, StockNews.com lowered Haemonetics from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system, and Donor360.